NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity.
BET inhibitors
Diagnosis
Epidemiology
Nut midline carcinoma
Treatment
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
23
02
2019
revised:
17
10
2019
accepted:
22
10
2019
pubmed:
11
11
2019
medline:
8
2
2020
entrez:
11
11
2019
Statut:
ppublish
Résumé
NMC is a recently recognized cancer type hallmarked by chromosomal translocation involving the NUT gene, a catastrophic event leading to fusion oncoprotein responsible for malignant transformation and tumor progression. The aggressiveness of disease together with a poor response to conventional treatment make NMC one of the most lethal cancer. Moreover, although until recently NMC has been poorly understood and largely neglected, the number of reported cases is steadily rising. Recently, in addition to its pathogenetic and diagnostic role, NUT-fusion oncoprotein has been shown to be amenable to targeted inhibition using BET inhibitors. Future clinical trials are warranted with the aim of investigate the incorporation of targeted agent into multimodal therapeutic strategy. Since new promising NUT-targeting drugs are emerging that may affect the clinical course, the correct and prompt recognition of NMC is key to improve patients' outcome.
Identifiants
pubmed: 31707223
pii: S1040-8428(19)30197-0
doi: 10.1016/j.critrevonc.2019.102826
pii:
doi:
Substances chimiques
Nuclear Proteins
0
Oncogene Proteins, Fusion
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102826Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.